MSFT 430.59 0.8407% AAPL 222.5 -0.1212% NVDA 119.1 -0.0336% GOOGL 157.46 1.7907% GOOG 158.37 1.8195% AMZN 186.49 -0.2727% META 524.62 -0.1865% AVGO 167.69 1.902% TSLA 230.29 0.2089% TSM 172.5 0.6242% LLY 923.71 -1.2096% V 287.35 0.6938% JPM 204.32 -1.1036% UNH 594.32 1.0027% NVO 137.0 0.2488% WMT 80.6 1.18% LVMUY 134.665 -0.226% XOM 111.15 -0.0719% LVMHF 675.14 0.1691% MA 493.36 0.254%
Last update at 2024-09-13T20:10:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -21.11000M | -14.26800M | -10.11600M | -15.38000M | -13.42100M |
| Minority interest | 0.00000M | 0.00100M | 0.07M | 0.08M | 0.05M |
| Net income | -19.68500M | -14.17400M | -9.99900M | -15.02000M | -13.36700M |
| Selling general administrative | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.09M | 0.09M | 0.20M | 0.24M | 0.27M |
| Ebit | -21.58100M | -14.36100M | -10.16000M | -15.66300M | -21.65400M |
| Ebitda | -21.45500M | -14.27400M | -9.95900M | -15.42300M | -21.38200M |
| Depreciation and amortization | 0.13M | 0.09M | 0.20M | 0.24M | 0.27M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -21.58100M | -14.27400M | -10.16000M | -15.66300M | -17.57100M |
| Other operating expenses | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M |
| Interest expense | -0.43000M | 0.09M | - | - | - |
| Tax provision | -1.42500M | - | - | - | - |
| Interest income | 0.51M | 0.00600M | 0.04M | 0.28M | 0.07M |
| Net interest income | 0.51M | 0.00600M | 0.04M | 0.28M | 0.07M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.42500M | -0.09400M | -0.11700M | -0.36000M | -4.20400M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 0.47M | 0.00600M | 0.04M | 0.28M | 4.08M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -19.68500M | -14.26800M | -10.11600M | -15.38000M | -13.42100M |
| Net income applicable to common shares | -19.68500M | -23.18900M | -12.55700M | -16.07600M | -25.29100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 71.86M | 70.36M | 8.41M | 17.23M | 30.14M |
| Intangible assets | 19.15M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.73M | 1.53M | 0.47M | 0.05M | - |
| Total liab | 17.30M | 4.96M | 3.15M | 5.75M | 3.69M |
| Total stockholder equity | 54.56M | 65.41M | 8.03M | 14.37M | 29.36M |
| Deferred long term liab | 19.15M | - | - | - | - |
| Other current liab | 5.87M | 2.91M | 1.79M | 2.71M | 2.35M |
| Common stock | 0.02M | 0.13M | 0.03M | 0.02M | 0.01M |
| Capital stock | 2.75M | 0.13M | 15.30M | 17.32M | 18.07M |
| Retained earnings | -290.96900M | -271.28400M | -248.09400M | -235.53700M | -219.46100M |
| Other liab | 8.83M | - | - | - | 0.30M |
| Good will | 5.53M | - | - | - | - |
| Other assets | 19.27M | 0.02M | 0.02M | 0.02M | 0.02M |
| Cash | 41.79M | 67.33M | 6.23M | 15.04M | 28.92M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 7.06M | 3.55M | 2.97M | 5.28M | 3.38M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -40.10500M | -65.79800M | -5.75400M | -14.32300M | -28.91800M |
| Short term debt | 0.27M | 0.12M | 0.29M | 0.25M | - |
| Short long term debt | 0.06M | - | - | - | - |
| Short long term debt total | 1.68M | 1.53M | 0.47M | 0.72M | - |
| Other stockholder equity | 343.46M | 336.56M | 240.82M | 232.58M | 230.75M |
| Property plant equipment | 1.54M | 1.48M | 0.45M | 0.79M | 0.61M |
| Total current assets | 45.52M | 68.86M | 7.93M | 16.43M | 29.51M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 46.30M | 65.41M | -7.24400M | -2.94000M | 11.31M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.23M | - | 0.47M | 0.00300M | - |
| Long term debt | 0.22M | - | - | - | - |
| Inventory | -0.23100M | - | - | - | - |
| Accounts payable | 0.92M | 0.52M | 0.89M | 2.31M | 1.03M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.67900M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.12M | 0.02M | 0.02M | 0.02M | 0.02M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 26.34M | 1.51M | 0.48M | 0.81M | 0.63M |
| Capital lease obligations | 1.40M | 1.53M | 0.47M | 0.72M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -4.39600M | -0.01400M | -0.00900M | 0.00000M | -0.00700M |
| Change to liabilities | -0.38500M | -0.36300M | -1.42900M | 1.28M | -0.98700M |
| Total cashflows from investing activities | -4.39600M | -0.01400M | -0.00900M | -0.00900M | -0.00700M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -1.93000M | 74.00M | 3.36M | 3.36M | 29.09M |
| Change to operating activities | -0.23800M | 1.24M | -1.35200M | -0.42700M | -1.20500M |
| Net income | -19.68500M | -14.26800M | -10.11600M | -15.38000M | -13.42100M |
| Change in cash | -25.44000M | 61.10M | -8.81800M | -13.87300M | 11.80M |
| Begin period cash flow | 67.33M | 6.23M | 15.04M | 28.92M | 17.12M |
| End period cash flow | 41.88M | 67.33M | 6.23M | 15.04M | 28.92M |
| Total cash from operating activities | -19.08200M | -12.89000M | -12.16800M | -13.87300M | -17.27900M |
| Issuance of capital stock | 2.73M | 65.96M | 3.36M | 0.00000M | 29.09M |
| Depreciation | 0.09M | 0.09M | 0.20M | 0.24M | 0.27M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | -0.28800M | - | - | - | - |
| Other cashflows from financing activities | -2.27200M | 8.04M | -0.00900M | -4.66400M | -0.00700M |
| Change to netincome | 1.14M | 0.41M | 0.46M | 0.34M | -1.99200M |
| Capital expenditures | 0.12M | 0.01M | 0.00900M | 0.00900M | 0.00700M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.80600M | 0.88M | -2.78100M | 0.85M | -2.19200M |
| Stock based compensation | 0.47M | 0.42M | 0.35M | 0.34M | 2.07M |
| Other non cash items | 2.27M | - | 0.18M | 0.07M | 0.07M |
| Free cash flow | -19.19800M | -12.90400M | -12.17700M | -13.87300M | -17.28600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| TOVX Theriva Biologics Inc. |
0.46 12.78% | 4.06 | - | - | - | 0.23 | 0.75 | |
| NVO Novo Nordisk A/S |
0.34 0.25% | 137.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.25 0.90% | 137.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
6.72 1.40% | 485.37 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-11.11 0.95% | 1153.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
9605 Medical Center Drive, Rockville, MD, United States, 20850
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven A. Shallcross CPA | CEO, CFO, Treasurer, Corp. Sec. & Director | 1961 |
| Dr. Frank Tufaro Ph.D. | Chief Operating Officer | 1955 |
| Vincent I. Perrone | Director of Corp. Communication | NA |
| Dr. Vince Wacher Ph.D. | Head of Product and Corp. Devel. | NA |
| Dr. Michael Kaleko M.D., Ph.D. | Sr. VP of R&D | NA |
| Ms. Lara M. Guzman | Sr. Director of Project Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...